Top Markets
#1 Ontology Gas Ontology Gas +26.62%
#2 EXOD EXOD +22.08%
#3 Status Status +17.01%
#4 Derive Derive +8.72%
#5 Gas Gas +7.44%
#6 Fake World Assets Fake World Assets +6.08%
#7 aelf aelf +5.83%
#8 Tornado Cash Tornado Cash +5.44%
#9 B3 (Base) B3 (Base) +5.37%
#10 DeFi Kingdoms DeFi Kingdoms +5.13%
Coin of the day
Ontology Gas Ontology Gas
Settings
Language
ENGLISH
Currency
USD
Theme
Recro Pharma, Inc. Recro Pharma, Inc.

Recro Pharma, Inc.

REPH
Rank in Stocks #25706
Recro Pharma, Inc. operates as a contract development and manufacturing... Recro Pharma, Inc. operates as a contract development and manufacturing organization (CDMO), offering comprehensive services for the development, production, and packaging of diverse therapeutic dosage forms. The company primarily specializes in small molecule therapeutic development, serving both domestic U.S. and international clients. Its extensive capabilities encompass a wide array of formats, including oral solid doses, sterile injectable solutions, oral liquid preparations, tablets, topical formulations, liquid/powder-filled capsules, ophthalmic droppers, liposomal products, and nano/microparticles. Furthermore, Recro Pharma provides specialized services such as aseptic fill/finish, lyophilization (freeze-drying), final packaging, and logistics management. Originally founded as Recro Pharma I, Inc., the company underwent a name change to Recro Pharma, Inc. in August 2008. The organization was established in 2007 and is headquartered in Exton, Pennsylvania.
Share Price
$2.09
Last synced: 2022-03-21
Market Cap
$47.04M
Change (1 day)
-0.48%
Change (1 year)
0.00%
Country
US
Trade Recro Pharma, Inc. (REPH)

Category

Healthcare
P/E ratio for Recro Pharma, Inc. (REPH)
P/E ratio as of 2026 TTM: 0
According to Recro Pharma, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Recro Pharma, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 38.29 -
IN
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.